Stifel on Sionna Therapeutics (SION): 'both compounds are able to attain exposures well above the modeled PK threshold'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $32.00 price target on Sionna Therapeutics (NASDAQ: SION)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
